# PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)

> **NCT06967272** · PHASE2 · RECRUITING · sponsor: **Sinovac Life Sciences Co., Ltd.** · enrollment: 400 (estimated)

## Conditions studied

- Rotavirus Gastroenteritis

## Interventions

- **BIOLOGICAL:** Oral hexavalent reassortant rotavirus attenuated live vaccine
- **BIOLOGICAL:** Oral hexavalent reassortant rotavirus attenuated live vaccine
- **BIOLOGICAL:** Oral pentavalent reassortant rotavirus attenuated live vaccine (controlled)

## Key facts

- **NCT ID:** NCT06967272
- **Lead sponsor:** Sinovac Life Sciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-20
- **Primary completion:** 2026-06-15
- **Final completion:** 2026-11-15
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06967272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06967272, "PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06967272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*